Table 7.

Sensitivity analyses of the effect of attributes on certainty of refusal (0–10) among serial non-demanders, January–March 2020.

Certainty	Sensitivity analyses for Serial non-demanders
	Analysis A (n = 49)		Analysis B (n = 49)		Analysis C (n = 67)		Analysis D (n = 31)
	Coefficient	95% CI	Coefficient	95% CI	Coefficient	95% CI	Coefficient	95% CI
Disease
Respiratory disease	ref		ref		ref		ref
Cancer	−0.42	[-1.32,0.49]	−0.12	[-0.68,0.44]	−0.30	[-0.96,0.36]	−0.20	[-1.06,0.67]
Genital warts	−0.01	[-0.22,0.20]	0.07	[-0.16,0.31]	−0.01	[-0.16,0.15]	0.12	[-0.25,0.48]
Safety
No side effect	ref		ref		ref		ref
Scientific surveillance	0.03	[-0.15,0.20]	0.11***	[0.05,0.17]	0.03	[-0.08,0.15]	0.18	[-0.01,0.36]
Safety other countries	−0.02	[-0.38,0.33]	−0.02	[-0.41,0.36]	−0.02	[-0.30,0.26]	−0.03	[-0.61,0.54]
Benefit/risk	0.11	[-0.65,0.86]	0.01	[-0.52,0.54	0.10	[-0.42,0.61]	0.00	[-0.83,0.83]
Indirect Protection
Protects only you	ref		ref		ref		ref
Protects other people	−0.05	[-0.74,0.63]	0.05	[-0.27,0.36]	−0.03	[-0.51,0.45]	0.07	[-0.44,0.57]
Elimination	0.14	[-0.56,0.84]	0.17***	[0.12,0.21]	0.12	[-0.38,0.61]	0.24***	[0.17,0.31]
Coverage
Not enough	ref		ref		ref		ref
Already a third	0.19	[-0.09,0.48]	0.00	[-0.17,0.17]	0.14	[-0.02,0.29]	−0.01	[-0.39,0.36]
Most adolescents	0.13	[-0.60,0.86]	0.11	[-0.24,0.47]	0.09	[-0.39,0.57]	0.19	[-0.39,0.77]
Other countries 80%	0.37	[-0.08,0.83]	0.26***	[0.12,0.39]	0.26	[-0.02,0.53]	0.42***	[0.23,0.61]

A: excluding participants with invariant certainty; B: excluding participants with low response time; C: excluding participants with both invariant certainty and low response time; D: excluding participants with at least one characteristic. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.